Aliases & Classifications for Amenorrhea

MalaCards integrated aliases for Amenorrhea:

Name: Amenorrhea 12 73 6 44 15 17 70
Absence of Menstruation 12
Amenia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:13938
ICD9CM 34 626.0
MeSH 44 D000568
NCIt 50 C61443
SNOMED-CT 67 156034000
ICD10 32 N91.2
UMLS 70 C0002453

Summaries for Amenorrhea

Disease Ontology : 12 A female reproductive system disease that is characterized by the absence of menstruation.

MalaCards based summary : Amenorrhea, also known as absence of menstruation, is related to hypogonadotropic hypogonadism 23 without anosmia and galactorrhea, and has symptoms including menometrorrhagia and ovulation bleeding. An important gene associated with Amenorrhea is FSHR (Follicle Stimulating Hormone Receptor), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Cyproterone Acetate and Leuprolide have been mentioned in the context of this disorder. Affiliated tissues include pituitary, ovary and bone, and related phenotypes are endocrine/exocrine gland and homeostasis/metabolism

Wikipedia : 73 Amenorrhea is the absence of a menstrual period in a woman of reproductive age. Physiological states of... more...

Related Diseases for Amenorrhea

Diseases related to Amenorrhea via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 641)
# Related Disease Score Top Affiliating Genes
1 hypogonadotropic hypogonadism 23 without anosmia 31.9 LHB GNRH1
2 galactorrhea 31.9 IGF1 PRL
3 blepharophimosis, ptosis, and epicanthus inversus 31.7 NR5A1 FOXL2 BMP15
4 hypogonadotropic hypogonadism 24 without anosmia 31.5 INS FSHB
5 46 xx gonadal dysgenesis 31.4 NR5A1 NOBOX LHCGR FSHR FOXL2 BMP15
6 pituitary adenoma, prolactin-secreting 31.3 PRL POMC NR5A1 IGF1 GNRH1
7 kallmann syndrome 31.1 WNT4 SHBG PRL NR5A1 LEP GNRH1
8 gonadal dysgenesis 31.1 SHBG NR5A1 FSHR FOXL2 BMP15
9 polycystic ovary syndrome 31.0 SHBG PRL LEP INS IGF1 GNRH1
10 pituitary tumors 30.9 PRL POMC IGF1
11 eating disorder 30.8 POMC LEP GHRL CRH
12 anorexia nervosa 30.7 SHBG PRL POMC LEP INS IGF1
13 hyperprolactinemia 30.6 SHBG PRL POMC INS IGF1 GNRH1
14 adenoma 30.6 PRL POMC LHCGR IGF1 CRH
15 pituitary adenoma 30.5 PRL POMC IGF1 GNRH1 CRH
16 diabetes insipidus 30.4 PRL POMC INS CRH
17 leydig cell tumor 30.4 PRL NR5A1 LHCGR GNRH1
18 lipoid congenital adrenal hyperplasia 30.4 POMC NR5A1 GNRH1
19 precocious puberty 30.4 LHCGR GNRH1 FSHR
20 ovarian cyst 30.4 PRL GNRH1 FOXL2
21 turner syndrome 30.3 SHBG LEP INS IGF1 BMP15
22 chromophobe adenoma 30.2 PRL POMC
23 pituitary hormone deficiency, combined, 2 30.2 PRL POMC IGF1
24 granulosa cell tumor of the ovary 30.2 PRL INS FOXL2
25 hermaphroditism 30.2 WNT4 SHBG FOXL2
26 pseudohermaphroditism 30.1 WNT4 POMC NR5A1 LHCGR LHB FSHR
27 hypogonadism 30.1 SHBG PRL LHCGR LHB LEP INS
28 nonsyndromic disorders of testicular development 30.1 WNT4 NR5A1
29 androgen insensitivity syndrome 30.1 SHBG NR5A1 INS
30 hypogonadotropic hypogonadism 30.1 SHBG PRL NR5A1 LHCGR LHB LEP
31 hypoglycemia 30.0 PRL POMC INS IGF1 CRH
32 bone resorption disease 30.0 LEP INS IGF1 ERCC6
33 craniopharyngioma 30.0 PRL NR5A1 INS IGF1 GNRH1 GHRL
34 adrenal adenoma 30.0 POMC INS CRH
35 acne 29.9 SHBG PRL POMC INS IGF1
36 hypothyroidism 29.9 SHBG PRL POMC LEP INS IGF1
37 acanthosis nigricans 29.9 SHBG PRL LEP INS IGF1
38 bulimia nervosa 29.9 LEP INS GHRL
39 prolactin producing pituitary tumor 29.9 PRL POMC
40 osteoporosis 29.9 SHBG PRL LEP INS IGF1 GNRH1
41 mental depression 29.9 POMC INS CRH
42 hyperandrogenism 29.9 WNT4 SHBG PRL POMC INS IGF1
43 major depressive disorder 29.9 PRL POMC LEP GHRL CRH
44 empty sella syndrome 29.8 PRL POMC INS IGF1 GNRH1
45 hypokalemia 29.8 POMC INS CRH
46 pseudohypoparathyroidism 29.8 PRL LEP IGF1
47 premenstrual tension 29.8 POMC GNRH1
48 pituitary gland disease 29.8 PRL POMC INS IGF1 GNRH1 CRH
49 insulin-like growth factor i 29.8 SHBG PRL LEP INS IGF1
50 hypoadrenocorticism, familial 29.8 POMC NR5A1 CRH

Graphical network of the top 20 diseases related to Amenorrhea:



Diseases related to Amenorrhea

Symptoms & Phenotypes for Amenorrhea

UMLS symptoms related to Amenorrhea:


menometrorrhagia; ovulation bleeding

MGI Mouse Phenotypes related to Amenorrhea:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.42 BMP15 CRH FOXL2 FSHB FSHR GHRL
2 homeostasis/metabolism MP:0005376 10.36 CRH ERCC6 FOXL2 FSHB FSHR GHRL
3 cellular MP:0005384 10.29 CRH ERCC6 FSHB FSHR IGF1 INS
4 growth/size/body region MP:0005378 10.29 CRH ERCC6 FOXL2 FSHR GNRH1 IGF1
5 adipose tissue MP:0005375 10.18 CRH ERCC6 FSHR GHRL IGF1 INS
6 immune system MP:0005387 10.17 CRH ERCC6 FSHR GNRH1 IGF1 INS
7 integument MP:0010771 10.1 CRH ERCC6 FSHR GNRH1 IGF1 INS
8 nervous system MP:0003631 10.03 CRH ERCC6 FSHR GNRH1 IGF1 INS
9 liver/biliary system MP:0005370 9.97 CRH ERCC6 GNRH1 INS LEP LHCGR
10 neoplasm MP:0002006 9.87 ERCC6 FSHR GNRH1 IGF1 LEP POMC
11 normal MP:0002873 9.81 CRH FOXL2 GHRL GNRH1 IGF1 INS
12 renal/urinary system MP:0005367 9.56 CRH GNRH1 IGF1 INS LEP LHCGR
13 reproductive system MP:0005389 9.47 BMP15 FOXL2 FSHB FSHR GNRH1 IGF1

Drugs & Therapeutics for Amenorrhea

Drugs for Amenorrhea (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 108)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyproterone Acetate Approved, Investigational Phase 4 427-51-0
2
Leuprolide Approved, Investigational Phase 4 53714-56-0 3911 657181
3
Levonorgestrel Approved, Investigational Phase 4 797-63-7, 17489-40-6 13109
4
Calcium carbonate Approved, Investigational Phase 4 471-34-1
5
Tibolone Approved, Investigational Phase 4 5630-53-5
6
Polyestradiol phosphate Approved Phase 4 28014-46-2
7
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
8
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
9
Cyproterone Phase 4 2098-66-0 5284537
10 Tin Fluorides Phase 4
11 Dacuronium Phase 4
12 Antipsychotic Agents Phase 4
13 Antineoplastic Agents, Hormonal Phase 4
14 Hormone Antagonists Phase 4
15 Estrogens Phase 4
16 Androgens Phase 4
17 Androgen Antagonists Phase 4
18 Estrogen Receptor Modulators Phase 4
19 Vitamins Phase 4
20 Calciferol Phase 4
21 Nutrients Phase 4
22 Trace Elements Phase 4
23 Micronutrients Phase 4
24 Anabolic Agents Phase 4
25 Antihypertensive Agents Phase 4
26 Calcium, Dietary Phase 4
27 Hormones Phase 4
28 Estradiol 3-benzoate Phase 4
29 Estradiol 17 beta-cypionate Phase 4
30
Calcium Nutraceutical Phase 4 7440-70-2 271
31
Medroxyprogesterone acetate Approved, Investigational Phase 3 71-58-9
32
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
33
Desogestrel Approved Phase 3 54024-22-5 40973
34
Goserelin Approved Phase 3 65807-02-5 47725 5311128
35
Toremifene Approved, Investigational Phase 3 89778-26-7 3005573
36
Progesterone Approved, Vet_approved Phase 3 57-83-0 5994
37
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
38 Prolactin Release-Inhibiting Factors Phase 3
39 Gonadotropins, Pituitary Phase 3
40 Follicle Stimulating Hormone Phase 3
41
Medroxyprogesterone Phase 3 520-85-4 10631
42 Contraceptive Agents, Male Phase 3
43 Progestins Phase 3
44
Moxifloxacin Approved, Investigational Phase 2 354812-41-2, 151096-09-2 152946
45
Flutamide Approved, Investigational Phase 2 13311-84-7 3397
46 Integrase Inhibitors Phase 2
47 Anti-Retroviral Agents Phase 2
48 HIV Integrase Inhibitors Phase 2
49 Antiviral Agents Phase 2
50 Raltegravir Potassium Phase 2

Interventional clinical trials:

(show top 50) (show all 79)
# Name Status NCT ID Phase Drugs
1 The Effects of Contraceptive Pill and Hormonal Vaginal Ring on Hormonal, Inflammatory and Metabolic Parameters in Women of Reproductive Age With Polycystic Ovary Syndrome (PCOS). Unknown status NCT01588873 Phase 4 oc:E-E-desogestrel/vaginal ring:E-E -ethonogestrel
2 Phase IV Study of the Use of Two Preparations of Ethinyl Estradiol and Cyproterone Acetate in Irregular Menstruation of Hyper-androgenic Origin Unknown status NCT01103518 Phase 4 Ethinyl Estradiol + Cyproterone acetate
3 Evaluation of Safety and Efficacy of PROMETRIUM® Capsules in Induction of Secretory Conversion of Endometrium and Withdrawal Bleeding in Subjects With Secondary Amenorrhea Completed NCT00160199 Phase 4 PROMETRIUM® 300 mg;PROMETRIUM® 400 mg
4 Metformin for Treatment Antipsychotic Induced Amenorrhea in Female Schizophrenic Patients: a Double Blind, Placebo-controlled Study Completed NCT01206153 Phase 4 metformin
5 Psychological Impact of Amenorrhea in Women With Endometriosis: Perspective Randomized Study Not yet recruiting NCT02393482 Phase 4 Estroprogestinic therapy (Etinil-estradiol/levonorgestre);Gonadotropin-releasing hormone agonist (Leuprorelin acetate);Add back therapy 1 (tibolone);Add back therapy 2 (calcium carbonate/colecalciferol)
6 The Luveris® In Vitro Fertilization Trial: The Effect of Recombinant Luteinizing Hormone on Follicular Response, Oocyte Quality, and Pregnancy in In-Vitro Fertilization Treatment Cycles in Women Without Endogenous LH Activity. Terminated NCT00889512 Phase 4 Luveris fixed dose;Luveris increasing dose
7 A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating Three Doses of Subcutaneous Pulsatile GnRH Administered Via OmniPod Pump for Ovulation Induction in Female Subjects With Primary Amenorrhea With Hypogonadotropic Hypogonadism Completed NCT01976728 Phase 3 Gonadorelin acetate subcutaneous (SC) 10 μg/pulse as a fixed dose, administered via. OmniPod pump;Gonadorelin acetate SC 15 μg/pulse as a fixed dose, administered via. OmniPod pump;Gonadorelin acetate SC 20 μg/pulse as a fixed dose, administered via. OmniPod pump;Placebo (SC 10, 15, or 20 μg/pulse as a fixed dose, administered via. OmniPod pump)
8 Parallel-Group Comparative Study of SJ-0021 and Purified Pituitary Gonadotropin in Subjects With Amenorrhea I or Anovulatory Cycles - Phase III Single-Blind Study Completed NCT01185782 Phase 3 Gonalef® (Follitropin alfa);Purified pituitary gonadotropin (Fertinorm-P®)
9 The Effect of Post Ablation Medroxyprogesterone Acetate on Endometrial Amenorrhea Rates: a RCT Recruiting NCT02449161 Phase 3 MPA;placebo
10 Investigating Reactivation of Ovarian Function Following Autologous PRP Intra-ovarian Infusion in Menopausal Women Recruiting NCT03916978 Phase 2, Phase 3
11 Fat Mediated Modulation of Reproductive and Endocrine Function in Young Athletes Active, not recruiting NCT00946192 Phase 3 Transdermal 17Beta-estradiol, progesterone;Ethinyl Estradiol + Desogestrel
12 Study of Adjuvant Toremifene With or Without Goserrelin in Premenopausal Women With Stage I-IIIA, Hormonal Receptor Positive Breast Cancer Accompanied With or Without Chemotherapy Induced Amenorrhoea Not yet recruiting NCT02132390 Phase 3 Goserelin;Toremifene
13 A Phase 3, Randomized, Three-Cycle, Double-Blind, Placebo-Controlled Study to Evaluate Induction of Secretory Conversion of Endometrium and Withdrawal Bleeding After Administration of TX-12-002-HR in Estrogen-Primed Women With Secondary Amenorrhea Terminated NCT02019589 Phase 3 Progesterone;Placebo
14 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of a 91-Day Extended-Cycle Combination Oral Contraceptive (Seasonale) for the Treatment of Low Bone Mineral Density in Adolescent Females With Secondary Amenorrhea and Osteopenia Withdrawn NCT00117260 Phase 3 Seasonale (levonorgestrel and ethinyl estradiol)
15 "2008P-00346: Bone Mass Accrual in Adolescent Athletes" Withdrawn NCT00827151 Phase 3 Estrogen
16 Compare the Different Routes of Administration of Misoprostol During Medicinal Abortion Between 7 and 9 Weeks of Amenorrhoea (SA) Withdrawn NCT03140384 Phase 3
17 Pulsatile GnRH in Anovulatory Infertility Unknown status NCT00383656 Phase 2 GnRH
18 Phase II Study of GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients Completed NCT00429494 Phase 2 Leuprolide Acetate
19 Evaluation of the Pharmacokinetic Properties and the Tolerance of Raltegravir During the Third Trimester of Pregnancy Completed NCT02099474 Phase 2
20 A Multicenter Study to Evaluate Induction of Withdrawal Bleeding After Administration of DR-2021 in Women With Secondary Amenorrhea Completed NCT00196391 Phase 2 DR-2021a;DR-2021b;DR-2021c;DR-2021d;DR-2021e
21 A Phase II Pilot Study to Evaluate the Safety and Efficacy of J867 Administered With Estrogen to Postmenopausal Women Completed NCT00152282 Phase 2 Asoprisnil/Premarin;Asoprisnil/Premarin;Asoprisnil/Premarin;Placebo and Premarin
22 Randomized, Double-blind, Placebo-controlled Trial of Human Recombinant Leptin (r-metHuLeptin) for the Treatment of Hypothalamic (Exercise-Induced) Amenorrhea Completed NCT00130117 Phase 2 r-metHuLeptin;Oral Contraceptive Pills (OCPs)
23 A Single-Blind, Placebo Run-in, Phase I/II Study Comparing Five Oral Doses of Proellex® Completed NCT01187043 Phase 1, Phase 2 Proellex
24 Androgen Excess as a Cause for Adipogenic Dysfunction in PCOS Women Recruiting NCT01889199 Phase 2 Flutamide
25 Atherosclerosis, Immune Mediated Inflammation and Hypoestrogenemia in Young Women Recruiting NCT03018366 Phase 2 17beta Estradiol;Transdermal placebo patch;Progesterone;Placebo Pill
26 Treatment of Menorrhagia in Women With Thrombocytopenia: Comparison of Platelet Transfusion Alone to Platelet Transfusion With Continuous Oral Contraceptive Pills Terminated NCT00556400 Phase 1, Phase 2 Lo-Ovral Oral Contraceptive Pills;Placebo - sugar pill
27 Turmeric Effect on Reduction of Serum Prolactin and Related Hormonal Change and Adenoma Size in Prolactinoma Patients Unknown status NCT01344291 Phase 1 Curcumin
28 An Open-Label, Escalating Dose, Single Center, Cross-over Design, Phase I Study to Evaluate Menses Induction in Women Administered Proellex Terminated NCT00881608 Phase 1 Placebo;Proellex
29 Estradiol and Fear Extinction for Calorie-Dense Foods in Weight Restored Adult Women With Anorexia Nervosa (AN) Withdrawn NCT02792153 Phase 1 Estradiol
30 Physiopathology of Bone Loss in Young Patient With Anorexia Nervosa Unknown status NCT01907464
31 Baselines in Reproductive Disorders Unknown status NCT00456274
32 Evaluation of the Protein Intake of the Pregnant Woman According to the Weight Status and in Pregnant Women Operated on Bariatric Surgery Unknown status NCT03669731
33 Effects of 6 Months of HRT on Total Antioxidant Capacity in Patients Affected by Hypotalamic Amenorrhea Unknown status NCT02984696 1 mg of transdermal estradiol daily and 10mg of oral MPA
34 The Cycle Disturbances, OLigomenorrhea and Amenorrhea (COLA) Study & Biobank Unknown status NCT02309047
35 Effect of Acupuncture and Diet Modification on Amenorrhea in Female Athlete Triad Unknown status NCT03817827
36 Description of Practices Implemented in the Birth of Living Children Before 24 Weeks of Amenorrhea Unknown status NCT03403894
37 Therapeutic Drug Monitoring of Gentamicin and Vancomycin, in Neonates, Using Dried Blood Spot Sampling. Unknown status NCT03651115
38 Variability of Uterine and Breast Development in Response to Exogenous Oestrogen During Induction of Puberty in Individuals With Hypogonadism. Unknown status NCT02871986 Routine transdermal oestrogen patch
39 Phenotyping and Genotyping of Women Presenting With Ovarian Dysfunction Associated With a Hypergonadotropic Hypo-estrogenic Hormonal Status (WHO III) and Their First and Second Degree Relatives Unknown status NCT01411644
40 KYleena Satisfaction Study / Observational Study on User Satisfaction With the Levonorgestrel Intrauterine Delivery System Kyleena (LNG-IUS 12) in New Contraceptive Users and After Switching From Another Contraceptive Method Completed NCT03182140 Kyleena
41 Hormone Dynamics and Bone Mineral Density in Anorexia Nervosa v. Hypothalamic Amenorrhea Completed NCT00556036
42 Organochlorine Compounds and Menstrual Cycle Function Completed NCT00011388
43 Assessment of Efficacy of Uterine Artery Doppler in Predicting the Response to Mefenamic Acid During Treatment of Women With IUCD Associated Menorrhagia Completed NCT03794895
44 Prospective Randomized Feasibility Study on the Self Application of Hydrotherapy to Treat Menopausal Symptoms Caused by Breast Cancer Therapy Completed NCT00243607
45 Ovarian Follicle Function in Patients With Primary Ovarian Insufficiency Completed NCT00001275
46 Impact of Intense Exercise Training on Energy Availability, Ovarian Function and Bone Turnover in Female Athletes Completed NCT02224976
47 Exercise Amenorrhea Stress and Bone Health in Adolescents Completed NCT00441402
48 Emergency Contraception as a Back up of Lactational Amenorrhea Method of Contraception Completed NCT01111929 Counseling for LAM+ LNG-EC
49 Mirena and Amenorrhea Related acceptabILity in Contraception indIcAtion Completed NCT01833793 Levonorgestrel IUD (Mirena, BAY86-5028)
50 Improvement of the Early Management and Thermal Comfort of Premature Infants Under 32 Weeks of Amenorrhea Placed in a Closed Incubator: Comparison of the Use of the Incubator in Conventional "Air" vs. "Cutaneous" Regulation Mode . Completed NCT03648606

Search NIH Clinical Center for Amenorrhea

Inferred drug relations via UMLS 70 / NDF-RT 51 :


17-alpha-Hydroxyprogesterone
2-Bromoergocryptine Mesylate
Bromocriptine
Gonadorelin
Gonadorelin Acetate
Gonadorelin Hydrochloride
hydroxyprogesterone caproate (USP)
Medroxyprogesterone
medroxyprogesterone acetate
norelgestromin
Norethynodrel
norgestimate
Progesterone
PROGESTERONE PWDR

Cochrane evidence based reviews: amenorrhea

Genetic Tests for Amenorrhea

Anatomical Context for Amenorrhea

MalaCards organs/tissues related to Amenorrhea:

40
Pituitary, Ovary, Bone, Uterus, Thyroid, Cervix, Placenta

Publications for Amenorrhea

Articles related to Amenorrhea:

(show top 50) (show all 10225)
# Title Authors PMID Year
1
Is Ovarian Reserve Impacted in Anorexia Nervosa? 61
33278562 2021
2
Autoimmunological serum parameters and bone mass density in premature ovarian insufficiency: a retrospective cohort study. 61
33169235 2021
3
Retroperitoneal ectopic pregnancy: A literature review of reported cases. 61
33640664 2021
4
Detection of pure Leydig cell ovarian tumor not visible on imaging by selective venous blood sampling in a woman with secondary amenorrhea and hirsutism: A case report. 61
33665140 2021
5
Postpartum amenorrhea duration by sex of the newborn in two natural fertility populations. 61
33314035 2021
6
Changes in marrow adipose tissue in relation to changes in bone parameters following estradiol replacement in adolescent and young adult females with functional hypothalamic amenorrhea. 61
33418100 2021
7
Recent advances in chemistry and bioactivity of Sargentodoxa cuneata. 61
33460761 2021
8
The Missing Uterus, the Missed Diagnosis, and the Missing Care. Mayer-Rokitansky-Küster-Hauser Syndrome in the Lives of Women in Malaysia. 61
33189898 2021
9
Identifying the risk factors and incidence of Asherman Syndrome in women with post-abortion uterine curettage. 61
33462894 2021
10
Genus Paeonia: A comprehensive review on traditional uses, phytochemistry, pharmacological activities, clinical application, and toxicology. 61
33346027 2021
11
Caesalpinia sappan induces apoptotic cell death in ectopic endometrial 12Z cells through suppressing pyruvate dehydrogenase kinase 1 expression. 61
33732330 2021
12
Fertility Issues in Polycystic Ovarian Disease: A Systematic Approach. 61
33518185 2021
13
A Randomized Clinical Trial of Levonorgestrel Intrauterine System with or without Metformin for Treatment of Endometrial Hyperplasia without Atypia in Indian Women. 61
33773565 2021
14
Predictors of bone mineral density in adolescents with atypical anorexia nervosa. 61
33712977 2021
15
High levels of physical activity in female adolescents with anorexia nervosa: medical and psychopathological correlates. 61
33704692 2021
16
Association of Self-Reported Polycystic Ovary Syndrome, Obesity, and Weight Gain From Adolescence to Adulthood With Hypertensive Disorders of Pregnancy: A Community-Based Approach. 61
33517680 2021
17
CHORIORETINAL CHANGES IN A GENETICALLY CONFIRMED CASE OF BOUCHER-NEUHÄUSER SYNDROME. 61
30015775 2021
18
Increased Burden of Rare Sequence Variants in GnRH-Associated Genes in Women With Hypothalamic Amenorrhea. 61
32870266 2021
19
Diagnosis and management of of primary amenorrhea and female delayed puberty. 61
33687345 2021
20
A new and feasible uterine compression suture technique in uterine atony to save mothers from postpartum hemorrhage. 61
33723106 2021
21
Human mesenchymal stem cell treatment of premature ovarian failure: new challenges and opportunities. 61
33658073 2021
22
Excision of deep endometriosis nodules of the parametrium and sacral roots in 10 steps. 61
33766459 2021
23
Does Genetic Susceptibility of the Gonadotropic Axis Explain the Variable Impact of Stressors Causing Functional Hypothalamic Amenorrhea? 61
32960961 2021
24
Timing of Uterine Artery Embolization for Leiomyoma during the Menstrual Cycle. 61
33468366 2021
25
Initial experience with HydroPearl microspheres for uterine artery embolization for the treatment of symptomatic uterine fibroids. 61
33788039 2021
26
Ulipristal acetate compared with leuprorelin acetate for Japanese women with symptomatic uterine fibroids: a phase III randomized controlled trial. 61
33715871 2021
27
The Role of Genetics, Epigenetics and Lifestyle in Polycystic Ovary Syndrome Development: the State of the Art. 61
33709373 2021
28
Chemotherapy-induced amenorrhea and its effects on fertility in long-term female survivors of classic osteosarcoma. 61
33772365 2021
29
Fertility and pregnancy outcome in gestational trophoblastic disease. 61
33649007 2021
30
Multidisciplinary team management of 46,XY 17α-hydroxylase deficiency: a case report and literature review. 61
33761789 2021
31
Relative energy deficiency in sports (RED-S): elucidation of endocrine changes affecting the health of males and females. 61
32557402 2021
32
Classification systems of Asherman's syndrome. An old problem with new directions. 61
33660561 2021
33
Sparganii Rhizoma: A review of traditional clinical application, processing, phytochemistry, pharmacology, and toxicity. 61
33181282 2021
34
Evaluating the menopausal transition with the STRAW + 10 in a Brazilian cohort of women with HIV, 2015-2016. 61
33709858 2021
35
Hemoperitoneum during removal of the placenta in advanced abdominal pregnancy with live fetus delivered at 37 weeks of gestation. A case report in a low-resource setting and literature review. 61
33676289 2021
36
Menstrual disorders associated with sirolimus treatment. 61
33369022 2021
37
Prevalence of lifetime eating disorders in infertile women seeking pregnancy with pulsatile gonadotropin-releasing hormone therapy. 61
32239478 2021
38
Management of perimenopause disorders: hormonal treatment. 61
33263443 2021
39
17α-hydroxylase/17,20 carbon chain lyase deficiency caused by p.Tyr329fs homozygous mutation: Three case reports. 61
33748243 2021
40
Management of interstitial pregnancy in the era of laparoscopy: a meta-analysis of 855 case studies compared with traditional techniques. 61
33539687 2021
41
Treatment-related fertility impairment in long-term female childhood, adolescent and young adult cancer survivors: investigating dose-effect relationships in a European case-control study (PanCareLIFE). 61
33744927 2021
42
Vesicouterine fistula presenting with cyclical haematuria mimicking bladder endometriosis: A case report. 61
33752291 2021
43
Genotypic Sex and Severity of the Disease Determine the Time of Clinical Presentation in Steroid 17α-Hydroxylase/17,20-Lyase Deficiency. 61
33780934 2021
44
Chance diagnosis of mixed gonadal dysgenesis in an adult case of malignant gonadal germ cell tumor: a case report. 61
33773600 2021
45
Efficacy of Sex Steroid Therapy Without Progestin or GnRH Agonist for Gonadal Suppression in Adult Transgender Patients. 61
33247919 2021
46
Satisfaction With Hormonal Treatment for Menstrual Suppression in Adolescents and Young Women With Disabilities. 61
33712384 2021
47
Autoimmune Diseases in Patients with Premature Ovarian Insufficiency-Our Current State of Knowledge. 61
33807517 2021
48
Menstrual cycle resumption and female fertility after autologous hematopoietic stem cell transplantation for multiple sclerosis. 61
33709839 2021
49
Cell-based endometrial regeneration: current status and future perspectives. 61
33650018 2021
50
Menstrual Dysfunction in Women With Schizophrenia During Risperidone Maintenance Treatment. 61
33538534 2021

Variations for Amenorrhea

ClinVar genetic disease variations for Amenorrhea:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 FSHR NM_000145.3(FSHR):c.2T>C (p.Met1Thr) SNV Pathogenic 523337 rs955385021 GRCh37: 2:49381555-49381555
GRCh38: 2:49154416-49154416
2 FSHR NM_000145.3(FSHR):c.153-11T>A SNV Uncertain significance 523336 rs1553340669 GRCh37: 2:49295440-49295440
GRCh38: 2:49068301-49068301

Expression for Amenorrhea

Search GEO for disease gene expression data for Amenorrhea.

Pathways for Amenorrhea

Pathways related to Amenorrhea according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.01 WNT4 POMC LHCGR LHB LEP INS
2
Show member pathways
13.43 WNT4 PRL POMC LHCGR LHB LEP
3
Show member pathways
12.91 POMC NR5A1 LHCGR LHB FSHR FSHB
4
Show member pathways
12.72 WNT4 POMC NR5A1 INS CRH
5
Show member pathways
12.31 PRL LHCGR LHB LEP INS
6 12.18 POMC LHCGR LHB GHRL FSHR FSHB
7
Show member pathways
12.06 POMC LHB LEP INS IGF1 GHRL
8 11.96 POMC LHCGR LHB FSHR FSHB CRH
9 11.71 WNT4 LEP INS IGF1
10 11.37 PRL LEP INS
11 11.16 NR5A1 LHCGR FSHR
12 10.87 LHCGR LHB INS IGF1 FSHR FSHB
13 10.85 PRL POMC LEP INS GHRL
14 10.47 LHCGR LHB GNRH1 FSHR FSHB
15 10.36 POMC CRH

GO Terms for Amenorrhea

Cellular components related to Amenorrhea according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.77 WNT4 SHBG PRL POMC LHB LEP
2 endoplasmic reticulum lumen GO:0005788 9.56 WNT4 INS GHRL BMP15
3 extracellular space GO:0005615 9.4 WNT4 PRL POMC LHB LEP INS
4 Golgi lumen GO:0005796 9.33 WNT4 LHB INS

Biological processes related to Amenorrhea according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.16 PRL POMC LHCGR LHB LEP INS
2 positive regulation of cell proliferation GO:0008284 10 PRL LEP INS IGF1 FSHB CRH
3 positive regulation of gene expression GO:0010628 9.99 NR5A1 INS IGF1 FSHB ERCC6 CRH
4 G protein-coupled receptor signaling pathway GO:0007186 9.97 POMC LHCGR LHB INS GNRH1 GHRL
5 cell-cell signaling GO:0007267 9.92 POMC LHB INS GNRH1
6 cellular protein metabolic process GO:0044267 9.91 PRL INS IGF1 BMP15
7 response to nutrient levels GO:0031667 9.82 PRL LEP GHRL
8 negative regulation of tumor necrosis factor production GO:0032720 9.79 POMC IGF1 GHRL
9 glucose metabolic process GO:0006006 9.78 LEP INS GHRL
10 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.73 LEP INS IGF1 FSHR
11 positive regulation of glycogen biosynthetic process GO:0045725 9.65 INS IGF1
12 regulation of osteoclast differentiation GO:0045670 9.65 FSHR FSHB
13 female gonad development GO:0008585 9.65 WNT4 NR5A1 FSHR
14 male gonad development GO:0008584 9.65 WNT4 NR5A1 LHCGR LHB FSHR
15 regulation of steroid biosynthetic process GO:0050810 9.64 NR5A1 LEP
16 male sex determination GO:0030238 9.63 NR5A1 GNRH1
17 adult feeding behavior GO:0008343 9.63 LEP GHRL
18 bone mineralization involved in bone maturation GO:0035630 9.6 LEP IGF1
19 Sertoli cell proliferation GO:0060011 9.59 FSHR FSHB
20 positive regulation of corticotropin secretion GO:0051461 9.58 GHRL CRH
21 ovulation cycle process GO:0022602 9.58 LHCGR FSHR
22 female gamete generation GO:0007292 9.58 FSHR FSHB BMP15
23 negative regulation of glucagon secretion GO:0070093 9.57 LEP CRH
24 positive regulation of cortisol secretion GO:0051464 9.56 GHRL CRH
25 follicle-stimulating hormone signaling pathway GO:0042699 9.55 FSHR FSHB
26 female pregnancy GO:0007565 9.55 PRL LEP GNRH1 FSHB CRH
27 progesterone biosynthetic process GO:0006701 9.54 LHB FSHB
28 hormone metabolic process GO:0042445 9.54 WNT4 NR5A1 LEP
29 negative regulation of circadian sleep/wake cycle, REM sleep GO:0042322 9.49 GHRL CRH
30 ovarian follicle development GO:0001541 9.35 LHCGR FSHR FSHB FOXL2 BMP15
31 hormone-mediated signaling pathway GO:0009755 9.1 NR5A1 LHCGR LHB GHRL FSHR FSHB

Molecular functions related to Amenorrhea according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.35 WNT4 POMC LHB LEP CRH
2 insulin-like growth factor receptor binding GO:0005159 9.32 INS IGF1
3 hormone activity GO:0005179 9.32 PRL POMC LHB LEP INS IGF1
4 protein tyrosine kinase activator activity GO:0030296 9.26 GHRL ERCC6
5 protein-hormone receptor activity GO:0016500 9.16 LHCGR FSHR

Sources for Amenorrhea

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....